Risultati della ricerca - C. Ryklansky

838 | A PHASE 1 TRIAL OF NX‐2127, A FIRST‐IN‐CLASS BTK DUAL‐TARGETED PROTEIN DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES Autoría: A. Danilov, M. Tees, H. Shah, C. Sun, I. Flinn, D. Ermann, J. Westin, M. Thirman, M. Co, A. Schwab, C. Ryklansky, M. Tan, E. Meredith, A. Wiestner